Inhibition of Mutated, Activated BRAF in Metastatic Melanoma

20103,527 citationsJournal Article

Authors

Keith T. Flaherty · Massachusetts General Hospital

Igor Puzanov · Vanderbilt University

Kevin B. Kim · The University of Texas MD Anderson Cancer Center

Antoni Ribas · UCLA Health

Grant A. McArthur · Peter MacCallum Cancer Centre

Jeffrey A. Sosman · Vanderbilt University

Peter J. O’Dwyer

Abstract

Treatment of metastatic melanoma with PLX4032 in patients with tumors that carry the V600E BRAF mutation resulted in complete or partial tumor regression in the majority of patients. (Funded by Plexxikon and Roche Pharmaceuticals.)

Topics & Keywords

Melanoma and MAPK Pathways Colorectal Cancer Treatments and Studies Cutaneous Melanoma Detection and Management

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: New England Journal of Medicine

Volume 363, Issue 9, pp. 809-819

DOI: 10.1056/nejmoa1002011

Field-Weighted Citation Impact: 197.13